While semaglutide is generally well tolerated, it is most commonly associated with gastrointestinal symptoms such as nausea or diarrhea, especially during the early stages of treatment or when the dose is increased
On October 7, compounding pharmacy advocacy groups, including the Outsourcing Facilities Association, sued the FDA, arguing that the agency did not follow the appropriate procedure and that its determination was based on flawed metrics that give an incomplete picture of demand for tirzepatide
Side effects Most common: nausea, vomiting, diarrhea, constipation, abdominal discomfort, headache, fatigue, injection-site reactions
[PMID: 8886450] PubMed record related to this compound for laboratory literature review
Schedule: Daily injections for 812 weeks (optional extension up to 16 weeks ), followed by a 24 week break for protocol cycling